Orgenesis

Orgenesis is a legitimate, publicly traded biotechnology company (NASDAQ: ORGS) specializing in decentralized cell and gene therapies, founded in 2008. The project has high intrinsic real-world utility and innovation potential through its POCare platform. However, the submission quality is critically poor, containing false claims (e.g., 'most people have used my product', 'audience reach: everyone'), incorrect naming ('DeepClaw'), and irrelevant tags ('film'). While the entity itself has verifiable traction (global partnerships, 140+ employees), its financial health is struggling (recent significant net losses) and the low-effort submission drastically undermines confidence, resulting in a score heavily penalized by quality factors.